DeSimone Colleen Elizabeth 4
4 · Syros Pharmaceuticals, Inc. · Filed Oct 23, 2017
Insider Transaction Report
Form 4
DeSimone Colleen Elizabeth
Principal Accounting Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2017-10-23−550→ 13,016 totalExercise: $3.04Exp: 2025-06-08→ Common Stock (550 underlying) - Exercise/Conversion
Common Stock
2017-10-23$3.04/sh+550$1,672→ 550 total - Sale
Common Stock
2017-10-23$16.06/sh−550$8,833→ 0 total
Footnotes (3)
- [F1]The sale reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate exercise price within the range.
- [F3]This stock option was granted on June 9, 2015. It vested as to 25% of the underlying shares on April 27, 2016 and vests as the remaining shares in equal monthly installments on the last day of each month until April 27, 2019.